Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.22 HKD | +0.38% | +3.57% | -21.39% |
02/05 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
10/04 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.39% | 63Cr | |
+26.37% | 4.82TCr | |
-1.01% | 4.17TCr | |
+43.96% | 4.1TCr | |
-5.31% | 2.88TCr | |
+9.34% | 2.56TCr | |
-21.69% | 1.9TCr | |
+6.23% | 1.29TCr | |
+26.99% | 1.2TCr | |
-3.38% | 1.18TCr |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology : Nomura Adjusts Alphamab Oncology's Price Target to HK$25.1 From HK$17.2, Keeps at Buy